Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA Completes Full Repayment of Goldman Sachs Loan

Sep 24, 2009 2:51pm EDT

XOMA to Develop Therapeutic Antibody for H1N1 and H5N1 Influenza Viruses Under $2.2 Million U.S. Government Program Managed by SRI International

Sep 23, 2009 3:00pm EDT

XOMA Receives Anticipated Deficiency Notice From NASDAQ

Sep 21, 2009 4:11pm EDT

XOMA Announces Plan to Fully Repay Goldman Sachs Loan

Sep 14, 2009 7:30am EDT

XOMA Announces $6 Million Antibody Discovery Collaboration With Arana Therapeutics

Sep 09, 2009 7:00am EDT

XOMA to Present At Two Upcoming Investor Conferences

Sep 04, 2009 7:00am EDT

XOMA to Present At Canaccord Adams Global Growth Conference On August 12, 2009

Aug 10, 2009 4:26pm EDT

XOMA Reports 2009 Second Quarter Financial Results

Aug 06, 2009 4:04pm EDT

XOMA to Announce Second Quarter 2009 Financial Results and Host Conference Call on August 6

Aug 03, 2009 4:02pm EDT

XOMA Announces New U.S. Government Biodefense Subcontract for Development of Therapeutic Antibodies to Treat SARS

Jul 30, 2009 7:00am EDT
RSS
  • Prev
    • 1...
    • 34
    • 35
    • 36
    • 37
    • 38
    • 39
    • 40
    • 41
    • 42
    • 43
    • ...48
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2025 XOMA Royalty Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2025 XOMA • Powered by GeneratePress
    Scroll back to top